{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:21:10Z","timestamp":1790911270290,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The severity of the bleeding phenotype in patients with hemophilia A (HA) broadly correlates with the degree of coagulation factor VIII (FVIII) deficiency in plasma. However, the FVIII level necessary to achieve the goal of zero joint bleeds remains unclear. This study aimed to identify the minimum FVIII level necessary to prevent joint bleeds in patients with HA. In this retrospective study, patients with congenital mild HA treated on demand, aged \u226516 years, with no history of FVIII inhibitors, followed at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milan, were enrolled. We investigated 270 male patients with a median age of 45 years (16-88) and median lifelong FVIII of 21 IU\/dL. One hundred patients (37%) had a lifelong history of at least 1 joint bleed. The mean annualized joint bleeding rate (AJBR) and spontaneous AJBR were 0.016 (standard deviation [SD], 0.032) and 0.001 (SD, 0.010), respectively. After adjusting for age, for each IU\/dL increase in FVIII, there was a 6% reduction in AJBR and an 11% reduction in spontaneous AJBR. The minimum FVIII levels needed to prevent lifelong any joint bleeds and spontaneous joint bleeds resulted to be 19.2 IU\/dL and 17.7 IU\/dL, respectively. In this large cohort of persons with mild HA, we identified the minimum FVIII levels needed to prevent total and spontaneous joint bleeds (19.2 IU\/dL and 17.7 IU\/dL, respectively). These findings could suggest important implications for the accurate design of prophylactic therapies for persons with moderate and severe HA, including gene therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023011366","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T16:51:46Z","timestamp":1698079906000},"page":"7209-7215","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A"],"prefix":"10.1182","volume":"7","author":[{"given":"Pasquale","family":"Agosti","sequence":"first","affiliation":[{"name":"1Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Fondazione Luigi Villa, Milan, Italy"},{"name":"2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Maria","family":"Siboni","sequence":"additional","affiliation":[{"name":"2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4539-545X","authenticated-orcid":false,"given":"Sara","family":"Scardo","sequence":"additional","affiliation":[{"name":"2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Torri","sequence":"additional","affiliation":[{"name":"2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-7624","authenticated-orcid":false,"given":"Roberta","family":"Gualtierotti","sequence":"additional","affiliation":[{"name":"1Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Fondazione Luigi Villa, Milan, Italy"},{"name":"2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"1Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Fondazione Luigi Villa, Milan, Italy"},{"name":"2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"issue":"23","key":"2023121116231463100_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023121116231463100_bib2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"14","key":"2023121116231463100_bib3","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"Kloosterman","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023121116231463100_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2516.2008.01837.x","article-title":"Clinical outcome of moderate haemophilia compared with severe and mild haemophilia","volume":"15","author":"den Uijl","year":"2009","journal-title":"Haemophilia"},{"issue":"5","key":"2023121116231463100_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/hae.13777","article-title":"Burden of mild haemophilia A: systematic literature review","volume":"25","author":"Peyvandi","year":"2019","journal-title":"Haemophilia"},{"issue":"10","key":"2023121116231463100_bib6","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/jth.15424","article-title":"Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019","volume":"19","author":"Hassan","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2023121116231463100_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","article-title":"Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients","volume":"115","author":"Nakajima","year":"2022","journal-title":"Int J Hematol"},{"issue":"5","key":"2023121116231463100_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.14372","article-title":"Adoption of emicizumab (Hemlibra\u00ae) for hemophilia A in Europe: data from the 2020 European Association for Haemophilia and Allied Disorders survey","volume":"27","author":"Krumb","year":"2021","journal-title":"Haemophilia"},{"issue":"9","key":"2023121116231463100_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023121116231463100_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40259-023-00615-4","article-title":"Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia","volume":"37","author":"Thornburg","year":"2023","journal-title":"BioDrugs"},{"issue":"8","key":"2023121116231463100_bib11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1055\/s-0035-1552562","article-title":"Targeting factor replacement therapy in severe hemophilia: which level is important?","volume":"41","author":"Fischer","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2023121116231463100_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hae.14201","article-title":"Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level?","volume":"27","author":"Collins","year":"2021","journal-title":"Haemophilia"},{"issue":"8","key":"2023121116231463100_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023121116231463100_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"16","key":"2023121116231463100_bib15","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"},{"key":"2023121116231463100_bib16","doi-asserted-by":"crossref","first-page":"1076029619862052","DOI":"10.1177\/1076029619862052","article-title":"Joint bleeding tendencies in adult patients with hemophilia: it's not all pharmacokinetics","volume":"25","author":"Zhou","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"2023121116231463100_bib17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis","volume":"120","author":"Chowdary","year":"2020","journal-title":"Thromb Haemost"},{"issue":"7","key":"2023121116231463100_bib18","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","article-title":"Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model","volume":"106","author":"Tiede","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2023121116231463100_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/hae.12905","article-title":"Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis","volume":"22","author":"Valentino","year":"2016","journal-title":"Haemophilia"},{"issue":"14","key":"2023121116231463100_bib20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2012.12727","article-title":"Association between physical activity and risk of bleeding in children with hemophilia","volume":"308","author":"Broderick","year":"2012","journal-title":"JAMA"},{"key":"2023121116231463100_bib21","doi-asserted-by":"crossref","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2023121116231463100_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"issue":"11","key":"2023121116231463100_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2023121116231463100_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2516.2011.02617.x","article-title":"The natural history of mild haemophilia: a 30-year single centre experience","volume":"18","author":"Tagliaferri","year":"2012","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7209\/2176362\/blooda_adv-2023-011366-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7209\/2176362\/blooda_adv-2023-011366-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T11:43:38Z","timestamp":1702295018000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/23\/7209\/498396\/Minimum-factor-VIII-levels-to-prevent-joint"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":24,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011366","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]}}}